Role of Low-Molecular-Weight Heparin in Unexplained Recurrent Pregnancy Loss
Not Applicable
Completed
- Conditions
- Pregnancy Loss
- Interventions
- Drug: Low molecular weight heparin
- Registration Number
- NCT06484634
- Lead Sponsor
- RESnTEC, Institute of Research
- Brief Summary
Using low-molecular-weight heparin (LMWH), outcomes such as live birth rate and the occurrence of pregnancy complications are some of the variables reported in some studies, with varying degrees of success. The present study aimed to compare the role of LMWH in unexplained recurrent pregnancy loss.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 175
Inclusion Criteria
- Pregnant females between 18 and 44 years of age
- Gestational age above 8 weeks
- A history of ≥3 consecutive first trimester pregnancy losses
Read More
Exclusion Criteria
- Patients with systemic lupus erythematosus
- Positive IgG and IgM anticardiolipin antibodies
- Positive for thrombophilia screening
- Any platelet function abnormality or a previous thromboembolic event requiring anticoagulant therapy (including heparin, aspirin or warfarin)
- Sensitive to acetylsalicylic acid, heparin, or warfarin
- Patients with any genetic, anatomical, or hormonal cause of recurrent pregnancy loss
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description LMWH Group Low molecular weight heparin Women received a daily dose of 40 mg of Low Molecular Weight Heparin subcutaneously.
- Primary Outcome Measures
Name Time Method Efficacy of Low-Molecular-Weight Heparin 32 weeks Efficacy was labeled as yes in terms of live births after the age of viability, i.e., 24 weeks of gestation.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
DG Khan Hospital
🇵🇰Dera Ghazi Khan, Punjab, Pakistan